Antiviral resistance and hepatitis B therapy #
Open accessThe DOI matches its Crossref record.
Abstract
The management of chronic hepatitis B currently rests with long-term therapy using oral nucleoside analogs. The major limitation of long-term therapy is antiviral resistance. Antiviral resistance is due to the high rate of mutations that can occur during hepatitis B virus (HBV) replication and the selection of these mutants due to a replication advantage in the presence of the antiviral agent. Indeed, high rates of antiviral resistance have been found with long-term use of lamivudine, in up to 76% of patients treated for 5 years or more. Rates of antiviral resistance are lower with adefovir therapy, ˜30% at 5 years. Newer more potent nucleoside analogs (tenofovir and entecavir) have proven to have much lower rates of antiviral resistance (<1% after 2 years in treatment-naïve subjects), but the long-term rates of resistance have yet to be fully defined. The appearance of these viral mutations (genotypic resistance) is usually followed by rises in HBV DNA levels (virological breakthrough) and then by rises in serum aminotransferase levels (biochemical breakthrough). The appearance of antiviral resistance can be accompanied by a transient but occasionally severe exacerbation of the underlying liver disease which in some instances has led to acute liver failure. Combinations of nucleoside analogs may offer an approach to preventing antiviral resistance, but the efficacy and safety of this approach have yet to be shown. A future research priority is to identify new agents active against HBV that target different steps in the viral life-cycle and might provide effective means to circumvent the antiviral resistance of nucleoside analogs. (Hepatology 2009;49:S174–S184.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
Sarrazin, C., & Zeuzem, S. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.11.055 · Cited by 504
Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B
Heathcote, E. J., Marcellin, P., Buti, M., Gane, E., De Man, R. A., Krastev, Z., Germanidis, G., Lee, S. S., Flisiak, R., Kaita, K., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.011 · Cited by 462
Subversion of Cellular Autophagy Machinery by Hepatitis B Virus for Viral Envelopment
Li, J., Liu, Y., Wang, Z., Liu, K., Wang, Y., Liu, J., Ding, H., & Yuan, Z. (2011) · Journal of Virology · doi:10.1128/jvi.02627-10 · Cited by 293
Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections
Li, X., Liu, X., Tian, L., & Chen, Y. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8465-4 · Cited by 104
Metadata
- Authors
- Ghany, M. G., & Doo, E. C.
- Venue
- Hepatology
- Published
- 2009-05
- Volume
- 49
- Issue
- Suppl. 5
- Pages
- S174-S184
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2141100327
- Cited by
- 222
- References
- 0
- FWCI
- 14.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiviral resistance and hepatitis B therapy #. https://app.cochat.ai/papers/10.1002/hep.22900
- The paper
- Ghany, M. G., & Doo, E. C. (2009). Antiviral resistance and hepatitis B therapy #. Hepatology. https://doi.org/10.1002/hep.22900
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.